ArticleJournal for immunotherapy of cancer2025
Onset and progression of atherosclerosis in patients with melanoma treated with immune checkpoint inhibitors.
Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Atherosclerotic Cardiovascular Disease and Cancer.Immunological reviews · 2026Review
- Immune-Checkpoint-Inhibitor-Related Cardiovascular Toxicities in Cancer: A Mechanistic Review of Molecular Pathways with AI-Assisted Literature Clustering.International journal of molecular sciences · 2026Review
- A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab.Frontiers in immunology · 2026Article
- Outcome of elective cemiplimab discontinuation in locally advanced or metastatic cutaneous squamous cell carcinoma patients achieving a complete remission.Frontiers in oncology · 2026Article
- Molecular Characterization and Pathogenicity of a Novel Recombinant NADC30-Like PRRSV Strain Isolated From Piglets Inducing Intestinal Inflammation, and Construction of Its Infectious Clone.Transboundary and emerging diseases · 2025Article
- Targeting ferroptosis, pyroptosis and necroptosis for cancer immunotherapy in melanoma: mechanistic insights and clinical perspectives.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) are effective anticancer agents but significantly increase cardiovascular risk. This could be due to its potential to induce or worsen atherosclerosis. We evaluated the onset and progression of atherosclerosis during ICI treatment in patients with melanoma and investigated risk factors for substantial (>10%/year) atherosclerotic plaque growth in five segments of the arterial tree.
methodsOnset and yearly progression of atherosclerosis were assessed in the aortic arch, descending thoracic aorta, abdominal aorta, left and right iliac arteries via CT scans performed prior to and 1 year (±3 months) after ICI therapy initiation in patients with melanoma in the adjuvant (resected melanoma) and advanced disease (irresectable stage III and stage IV) setting. The primary outcome was defined as yearly progression of maximal plaque thickness in each arterial segment. Secondary outcomes were changes in the number of plaques, incidence of arterial thrombosis (ATE), and factors associated with substantial plaque growth in the descending thoracic aorta.
resultsIn total, 244 patients were included. Plaque thickness increased significantly in all aortic segments, ranging from 3.0% to 8.0% per year (all p<0.001). In 75% of included patients, substantial plaque growth in ≥1 segment occurred. Number of plaques remained identical in 64-86% of arterial segments. Three (1.2%) developed ATE within 1 year after ICI initiation. ICI combination therapy demonstrated a trend towards increased risk of substantial plaque growth compared with monotherapy (OR 2.10 (95% CI, 0.95 to 4.66; p=0.068)), whereas antihypertensive drug usage was associated with a lower risk (OR 0.48 (95% CI, 0.24 to 0.95; p=0.036)).
conclusionThe majority of patients with melanoma experience substantial atherosclerotic plaque growth during ICI therapy. The number of plaques remained relatively stable, suggesting that ICIs could particularly affect pre-existing plaques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.